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Abstract
Cirrhotic patients with recurrent variceal bleeds who 
have failed prior medical and endoscopic therapies and 
are not transjugular intrahepatic portosystemic shunt 
candidates face a grim prognosis with limited options. 
We propose that mesocaval shunting be offered to this 
group of patients as it has the potential to decrease 
portal pressures and thus decrease the risk of recurrent 
variceal bleeding. Mesocaval shunts are stent grafts 
placed by interventional radiologists between the me-
senteric system, most often the superior mesenteric 
vein, and the inferior vena cava. This allows flow to 
bypass the congested hepatic system, reducing portal 
pressures. This technique avoids the general anesthesia 
and morbidity associated with surgical shunt placement 
and has been successful in several case reports. In this 
paper we review the technique, candidate selection, 
potential pitfalls and benefits of mesocaval shunt place-
ment. 
Key words: Portal hypertension; Surgical portacaval 
shunt; Gastrointestinal hemorrhage; Esophageal and 
gastric varices; Transjugular intrahepatic portasystemic 
shunt
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Core tip: Cirrhotic patients who have recurrent variceal 
hemorrhage despite medical and endoscopic therapy 
have limited options if they are not transjugular intrahe-
patic portosystemic shunting candidates. One promising 
new method to decrease portal pressures while avoiding 
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surgical shunt placement is mesocaval shunt placement 
with fluoroscopic guidance. In this paper we review the 
technique, candidate selection, potential pitfalls and 
benefits of mesocaval shunt placement. 
Davis J, Chun AK, Borum ML. Could there be light at the end of 
the tunnel? Mesocaval shunting for refractory esophageal varices 
in patients with contraindications to transjugular intrahepatic 
portosystemic shunt. World J Hepatol 2016; 8(19): 790-795 
Available from: URL: http://www.wjgnet.com/1948-5182/full/
v8/i19/790.htm  DOI: http://dx.doi.org/10.4254/wjh.v8.i19.790
INTRODUCTION
Patients with cirrhosis and recurrent variceal bleeding 
face a high mortality, 20% in the first year vs 5.4% for 
compensated patients[1]. Current standard of care for 
variceal bleeding includes three primary modalities: 
Medical therapy with beta blockade, endoscopic the­
rapy with ligation of varices and shunt therapy with 
transjugular intrahepatic portosystemic shunting (TIPS). 
Each of these have been shown to improve rebleeding 
rates and mortality[2­4]. 
For an unfortunate cohort of patients with varices who 
fail medical and endoscopic therapy and are not TIPS 
candidates, there are limited options in the face of a grim 
prognosis. Historically, these patients have been offered 
surgical shunt approaches, however, mortality of surgical 
shunt placements is high ­ 20%­50% if emergent ­ and 
many patients may not be suitable surgical candidates[5]. 
First described in 1996 by Nyman et al[6], mesocaval 
shunting may provide an alternate route to alleviate 
portal hypertension in these challenging patients. This 
paper will review the technique, candidate selection, 
potential pitfalls and benefits of mesocaval shunting. 
While there are not enough data to comment on a mor­
tality benefit, we believe that mesocaval shunting is a 
feasible procedure for the prevention of variceal bleeding. 
It will likely be most useful for patients whose anatomy 
prohibits TIPS to provide a bridge to transplant. 
TECHNIQUE
Mesocaval shunting involves the creation of a shunt 
from the mesenteric vasculature, typically the superior 
mesenteric vein (SMV), into the inferior vena cava 
(IVC). Similar to TIPS, this provides relief of portal pre­
ssures by allowing blood to bypass the congested 
hepatic vasculature. Shunt placement is performed by 
interventional radiologists. There have been both femoral 
and transabdominal approaches reported (Table 1)[6­9]. 
Fluoroscopy from a recent case of refractory variceal 
bleeding in a patient with a portal vein thrombus (PVT) 
from our institution will be used to graphically illustrate 
the basic technique (Figure 1). Our patient had cirrhosis 
and prior medical and endoscopic attempts to control her 
varices were limited by significant chest pain attributed 
to her banding procedures that required inpatient 
admission. Her PVT prohibited TIPS placement and she 
consented to undergo endovascular mesocaval shunt 
placement.
In our patient, and, in general, first, a needle is dir­
ected, in our case transabdominally, through the SMV, 
or, in this instance, a portal vein remnant, at a target 
placed via internal jugular (IJ) access (Figure 2A). Then, 
a wire is threaded from this needle through the IVC and 
out the IJ access so that, when the needle is removed, 
the distal tip of the the wire is in the splenic vein and 
its proximal end functions as a guidewire exiting the IJ 
access (Figure 2B). Finally, a stent graft, in our case a 
covered VIATORR stent, is passed over the guidewire 
via IJ access using Seldinger technique and placement 
is confirmed with fluoroscopic guidance (Figure 2C). 
In the initial case report[6], contrast­enhanced com­
puted tomography (CT) was first performed to define 
cross­sectional anatomy. The patient underwent bowel 
preparation pre­procedurally and was given prophylactic 
antibiotics as a transcolonic approach was anticipated. 
Using CT and fluoroscopic guidance, a needle was inserted 
through and through the transverse colon and SMV into 
the IVC to a retrieval basket. The retrieval basket had 
been placed in the IVC via the right internal jugular vein. 
A guide wire was then passed from the abdominal access 
through the SMV to IVC and jugular access. A stent was 
placed under angiographic guidance from the internal 
jugular access across the IVC to SMV and the wire was 
removed. 
Another case report, by Moriarty et al[9], used similar 
methodology but opted for a transgastric rather than 
transcolonic approach to reduce the risk of infection. 
Interestingly, the case reported by Moriarty et al[9] re­
quired a cardiac transseptal needle to puncture the IVC 
as attempts made with a Rosch­Uchida TIPS needle 
were unsuccessful. The final published percutaneous 
approach to date was remarkable for the ability to avoid 
luminal puncture; Bercu et al[8] were able to approach 
transabdominally without perforating the bowel and relied 
on fluoroscopic rather than CT­guidance for visualization 
of the patient’s anatomy during the procedure. 
Hong et al[7] reported an interesting series of three 
cases in which they were able to place mesocaval shunts 
but avoid a transabdominal approach. Using techni­
ques similar to direct intra­hepatic portosystemic shunt 
(DIPS) placement, they describe a series of cases in 
which they relied on intravascular ultrasound to avoid 
transabdominal puncture to access the SMV. The stent 
itself is extra­hepatic (and thus distinct from DIPS) and 
possible in patients who are not candidates for TIPS or 
DIPS given portal vein thrombi. In short, sheaths were 
placed both femorally and in the internal jugular vein. A 
guide wire was used to couple the jugular and femoral 
sheaths. Following guide wire placement, a longitudinal 
side­firing intravascular ultrasound (IVUS), akin to those 
used in placement of DIPS, was introduced through the 
femoral sheath so that the SMV could be cannulated 
using a needle introduced at the jugular access. In this 
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way, they were able to avoid a percutaneous transab­
dominal approach altogether. It should be noted that the 
third patient included in this series was not a cirrhotic 
patient but rather had portal and SMV clots due to a 
pancreatic tumor; we chose to include this patient in our 
review to demonstrate the feasibility of the procedure but 
appreciate that his underlying pathophysiology may be 
different from the others presented. 
SELECTION OF CANDIDATES
Candidates likely to benefit from mesocaval shunt­
ing include those with recurrent variceal bleeds who 
have failed prior medical and endoscopic therapies. 
Traditionally, TIPS has been employed in these patients 
to alleviate portal pressures. We propose that mesocaval 
shunting be offered to patients who are not TIPS can­
didates, particularly the group awaiting transplant, as 
there are not yet mortality data for mesocaval shunting 
and the mortality benefit of other portosystemic shunts, 
including TIPs, has been questioned[10].
As in our illustrative case, PVT, for example, are known 
to make TIPS more difficult and result in lower success 
rates, ranging from 40%­75%[11]. In some cases, when 
PVT is chronic, TIPS is not only difficult but actually tech­
nically impossible as in order to re­establish flow, there 
must be functional vessels surrounding the planned 
recanalized clot segment. This intact vasculature is 
often absent in those with chronic PVT as intrahepatic 
vessels may have atrophied while extrahepatic vessels 
form collaterals at high risk of bleeding[6]. Given the 
relatively high prevalence of PVT in cirrhotics, up to 5% 
to 16% of patients at the time of liver transplantation, 
mesocaval shunting has the potential to offer a therapy 
Ref. Case history Details and outcomes
Nyman et al[6] 1996 37-year-old male with history of recurrent massive variceal bleeds 
attributed to congenital PVT and failed prior surgical shunt attempt
Visualization CT angiography
Approach Transcolonic
Duration of follow-up 5, 12 and 14 mo
Thrombosis Yes1
Recurrent bleeding No
Hepatic encephalopathy NR
Moriarty et al[9] 2012 57-year-old male with history of metastatic CRC and extrahepatic PVT 
who failed prior TIPs and was thought not to be surgical candidate
Visualization CT and fluoroscopy
Approach Transgastric
Duration of follow-up 3 mo
Thrombosis Yes2
Recurrent bleeding Yes2
Hepatic encephalopathy NR
Bercu et al[8] 2015 58-year-old female with history of HCV cirrhosis, PVT with recurrent 
ascites who failed prior TIPs attempt and was a poor surgical candidate
Visualization Fluoroscopy
Approach Transabdominal
Duration of follow-up 3 and 6 mo
Thrombosis No
Recurrent bleeding No
Hepatic encephalopathy Yes3
Hong et al[7] 2012 16-year-old female with history of chronic PVT and hematemesis who 
was felt to have high surgical risk
Visualization Fluoroscopy and IVUS
Approach Endovascular
Duration of follow-up 1 mo
Thrombosis No
Recurrent bleeding No
Hepatic encephalopathy NR
Hong et al[7] 2012 60-year-old female with history of HBV, HCV, HCC with thrombus 
obliterating PV
Visualization Fluoroscopy and IVUS
Approach Endovascular
Duration of follow-up 2 and 10 mo
Thrombosis No
Recurrent bleeding No
Hepatic encephalopathy NR
Hong et al[7] 2012 53-year-old male with history of pancreatic teratoma treated with 
Whipple with clot at SMV and splenic veins
Visualization Fluoroscopy and IVUS
Approach Endovascular
Duration of follow-up 1 and 3 mo
Thrombosis No
Recurrent bleeding No
Hepatic encephalopathy NR
Table 1  Summary of published mesocaval shunt placements
1The shunt was found to be thrombosed on POD #1 so the patient underwent ballooning of his stent and directed thrombolysis and was started on a 
therapeutic heparin. His hematocrit began to fall on the heparin but stabilized when the anticoagulation was held; 2The shunt was found to be thrombosed on 
POD #2 and on POD #3 the patient had a recurrent upper gastrointestinal hemorrhage. A new shunt was placed and the patient had no further bleeding; 3The 
patient had no encephalopathy at a 3-mo follow-up visit but was noted by an outside hospital to have encephalopathy 6 mo after shunt placement when the 
patient was hospitalized for concern for partial small bowel obstruction. The patient’s home lactulose and rifaximin had been held; when these medicines were 
resumed her encephalopathy resolved. NR: Not reported; PVT: Portal vein thrombus; CRC: Colorectal cancer; TIPs: Transjugular intrahepatic portosystemic 
shunting; HCV: Hepatitis C virus; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; SMV: Superior mesenteric vein; PV: Portal vein; CT: Computed 
tomography.
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to a large group of patients who were previously thought 
to be without options, particularly in those patients whose 
PVT prohibits them from receiving a liver transplant[12]. 
Prior to endovascular placement of mesocaval shunts, 
the other option for patients in this scenario was sur­
gical shunt placement. Historically, surgically placed 
portosystemic shunts have had high mortality[5]. While 
experienced centers are reporting improved opera­
tive mortality[13,14], the ability to replicate these lower 
mortality rates at smaller, less experienced centers 
remains to be seen. Furthermore, several of the patients 
in published percutaneous mesocaval shunt cases to 
date were thought to be poor surgical shunt candidates 
due to a history of prior abdominal surgeries and/or 
anatomy of their PVT[6,8,9].
If a patient is felt to be appropriate for consideration 
of mesocaval shunt placement, assessment of cross­
sectional anatomy should be undertaken with computed 
tomography or magnetic resonance imaging of the 
abdomen to assist in procedural planning. For successful 
shunt placement, the IVC and SMV should be aligned 
and proximal in an anatomic window without any signi­
ficant vasculature or viscera interposed between the two 
vessels[8]. The IVC and SMV (or a large collateral) must 
be patent for shunt placement. 
POTENTIAL PITFALLS
There are a few potential pitfalls we consider with place­
ment of a mesocaval shunt. First, similar to the surgical 
expertise required for safe surgical shunt placement, 
institutional interventional radiologic expertise will be 
required to safely recommend this procedure and this 
may not be available at all centers. This procedure, 
unlike TIPS, has not been reported to be performed in 
the setting of active variceal bleeding and thus there are 
no data to support its safety in that setting.
The most serious risk is that of procedure­related 
hemorrhage due to puncture of proximal vasculature. 
As noted by Hong et al[7] both the SMV and infrahepatic 
IVC lack any surrounding solid organs that could provide 
tamponade during shunt placement, creating a risk 
of major hemorrhage. Of the published cases to date, 
one noted intraabdominal hemorrhage­multiple small 
bowel hematomas ­ which was successfully treated 
conservatively with intravenous fluid, transfusion support 
and discontinuation of anticoagulation[6]. If the cannulated 
vesels require predilation prior to shunt placement, this 
risk of bleeding is likely increased[7]. Finally, while they 
did not experience intrabdominal hemorrhage despite 
use of an uncovered stent, Moriarty et al[9] note that use 
of an uncovered stent certainly increases risk of bleeding 
and recommend using covered stents and/or balloons to 
minimize this risk. In addition to procedural technique, 
we anticipate that, similar to other invasive procedures 
in cirrhotic patients, platelet counts influence the risk of 
hemorrhage. The cases reviewed here unfortunately do 
not provide patient platelet counts or other measures of 
clotting function. 
In addition to the potential for vessel perforation, 
depending on each individual patient’s anatomy, there 
are risks of perforation of different structures. If an intes­
tinal perforation is created, risk of sepsis, hemorrhage 
and/or abscess formation will certainly be increased[8]. 
In two reported cases, the transabdominal approach 
necessitated intestinal puncture[6,9]. In one case the 
track was transcolonic while the other approach was 
transgastric. Bowel preparation and antibiotic prophylaxis 
were administered in the transcolonic case and neither 
case resulted in sepsis. Although there were no reported 
infectious complications in the cases we reviewed, this 
risk should be underscored as it is likely not negligible in 
cirrhotic patients with impaired immunity. In addition to 
the risk of intestinal perforation, other nearby viscera are 
at risk of puncture as well. If the pancreas is punctured, 
both hemorrhage and pancreatitis are potential risks[8]. 
One published case to date notes pancreatic bisection 
and reports that serum amylase levels were within the 
normal range for at least five days post­operatively[7]. 
In the six cases reviewed, two cases reported sub­
sequent shunt occlusion and need for further revision, 
a rate of 33% in our, appreciably, small series. Shunt 
thrombosis is an important outcome as it presumably 
puts the patient at risk for further portal hypertension, 
variceal formation and variceal bleeding. In the first of the 
two cases complicated by occlusion, lack of flow through 
the shunt was noted on both Doppler and CT on POD 
#2[6]. The patient underwent repeat angiography and 
had ballooning and directed thrombolysis of his stent with 
subsequent patency on 5 mo follow­up angiogram. The 
stent was again noted to be occluded on 12 mo follow­
up angiography but he had no further gastrointestinal 
bleeding and no attempt to revise the shunt further was 
made. In the second case complicated by shunt occlusion, 
lack of flow through the shunt was noted on POD #2 on 
CT[9]. This was attributed to the severe angle of the initial 
shunt placement and its proximity to the wall of the IVC. 
This patient experienced upper gastrointestinal bleeding 
on POD #3 and underwent repeat angiography with 
stent replacement and had a patent stent and no further 
bleeding at 3 mo follow­up.
Finally, as with any form of portosystemic shunting, 
we anticipate that these patients will have higher rates 
Figure 1  Grade Ⅲ varices in distal esophagus on pre-procedure esopha-
gogastroduodenoscopy. 
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of hepatic encephalopathy (HE) than patients without 
portosystemic shunting. Given the limited numbers of 
patients who have undergone percutaneous or endo­
vascular mesocaval shunt placement, there are no 
data to evaluate rates of HE with these shunts vs TIPS 
or surgical shunt creation but presumably the rate is 
similar, around 30%[15,16]. In the cases reviewed above, 
only one case reported on the presence or absence of 
encephalopathy. In that case, the patient was noted to 
have no encephalopathy during index hospitalization or 
at 3 mo follow­up but was noted to be encephalopathic 
6 mo post­operatively when her lactulose and rifaximin 
were held at an outside hospital for partial small bowel 
obstruction[8]. Her encephalopathy reportedly resolved 
with resumption of these medications.
BENEFITS
As above, mesocaval shunting offers a treatment for 
bleeding varices for patients who otherwise face a high 
mortality with virtually no options. It can be offered to 
patients with PVT who cannot undergo TIPS and may 
be best utilized as a bridge to transplant. Furthermore, 
if an IVUS is utilized, vessels are directly visualized, 
avoiding the blind puncture method used in TIPS[7]. As 
with other similar endovascular procedures, we anticipate 
a lower mortality with this less invasive approach vs 
surgical shunt placement. Regardless, the majority of 
the published patients to date were not felt to be surgical 
candidates[6,7,9]. 
In the six adult cases published to date, two stents 
thrombosed within two days post­operatively while the 
remaining four remained patent[6,9]. Of the two patients 
with shunt thrombosis, one had a recurrent upper gas­
trointestinal bleed. In this case, it was postulated that 
the severe angle of the initial stent placement may have 
contributed to turbulence and subsequent thrombosis[9]. 
In both cases, subsequent shunt revision was performed 
and the revised shunts remained open during five and 
three months follow­up respectively. One shunt ultimately 
lacked patency at 12 mo follow­up but the patient had 
no further bleeding up to 14 mo follow­up. In summary, 
all reported cases have follow­up ranging from 1 to 14 
mo in which, with the exception of the post­operative 
day 2 bleed noted above, there were no further variceal 
bleeding episodes. These are promising results in light of 
the known 60% 1­year risk of rebleeding and 33% 1­year 
mortality in patients who survive an episode of variceal 
hemorrhage[17].
In addition to offering a rescue therapy for a group 
of patients with minimal options, mesocaval shunting 
has an advantage compared to local variceal therapy, it 
will result in lower portal pressures and thus will reduce 
recurrent ascites as well reducing the risk of variceal 
bleeding. As noted by Garcia­Tsao and Bosch in a recent 
review, judgment of treatment success of varices 
should include mindfulness about the impact of variceal 
treatment on other complications of portal hypertension­
ascites, jaundice, encephalopathy ­ rather than artificially 
isolating the treatment’s impact on variceal bleeding 
alone[17]. Finally, given that the presence of portal vein 
thrombosis is no longer thought to be an absolute con­
traindication to transplant[18], for those patients that 
are transplant eligible, placement of a mesocaval shunt 
may enable survival to the operating room table for 
transplant, a pressing concern given that our most recent 
national statistics are dire. In 2014, 1821 patients died 
while awaiting transplant and an additional 1290 were 
removed from the waiting list as they were felt to be “too 
sick” for transplant[19]. 
CONCLUSION
As reviewed above, endovascular mesocaval shunting is 
a feasible procedure that offers a promising intervention 
to a patient population with few options and one­year 
mortality as high as 20%[1]. TIPS has been shown to be 
an effective intervention to prevent recurrent variceal 
Davis J et al . Mesocaval shunting for esophageal varices
A B C
Figure 2  Intra-procedure steep oblique fluoroscopy of upper abdomen during mesocaval shunt placement. First, a needle is inserted percutaneously (black 
arrowhead) and directed through the portal vein remnant at a target snare placed in the inferior vena cava (white arrowhead) via internal jugular (IJ) access sheath 
(red arrowhead) (A). The wire is then threaded from its original percutaneous entry via the needle through the IJ sheath (red arrowhead) so that it extends from the 
IJ and is seen coiling in the splenic vein (black arrowhead) (B). The unexpanded stent graft (white arrowhead) is passed over the wire using Seldinger technique with 
fluoroscopic guidance (B). Coils are placed in varices (blue arrowhead) (B). Shuntogram with contrast 22 mo post-procedure shows functioning mesocaval shunt (white 
arrowhead) with tip in the splenic vein (black arrowhead) and absent varices (C). Previous coils in the varices are still visible (red arrowhead). 
RT
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bleeding[2] and mesocaval shunting provides similar 
physiologic relief of portal pressure in patients who are 
not TIPS candidates. Like TIPS, mesocaval shunting 
avoids major surgery and may require less anesthesia 
than a surgical shunt approach. Furthermore, it can be 
offered to patients who are not surgical candidates. 
Mesocaval shunting alleviates portal hypertension, a key 
component of reducing the rate of variceal bleeding, 
and one that will potentially reduce recurrent ascites 
as well. The patient who stands to gain the most from 
this procedure has recurrent variceal bleeds, has failed 
endoscopic and medical therapies, cannot undergo 
TIPS due to anatomy and needs a bridge to transplant 
to minimize the chance of further decompensating 
while awaiting an organ. In order to have successful 
shunt placement, these patients must have alignment 
between IVC and SMV or SMV collaterals. Potential 
procedural complications include perforation of nearby 
vessels or viscera which could result in hemorrhage, 
sepsis, pancreatitis or abscess formation as well as 
stent thrombosis. Placement of a portosystemic shunt 
will also increase the risk of hepatic encephalopathy 
although there is little data to compare mesocaval shunts 
to surgical shunts or TIPS. To date, several approaches 
and imaging techniques have been utilized by reporting 
groups, notably including one approach that avoids tran­
sabdominal puncture[7]. In the cases reported, all have 
prevented rebleeding for the post­procedural monitoring 
period after initial shunt or initial shunt revision[6,8,9]. 
Further research should be performed to better assess 
outcomes ­ variceal bleeding, hepatic encephalopathy 
rates and mortality ­ in these patients compared to 
standard­of­care controls so that the benefits of this 
promising technique may be maximized. 
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